Table 1.
Treatment summary
Patient 1 | Patient 2 | Patient 3 | Patient 4 | |
---|---|---|---|---|
Gender | M | M | M | F |
Age of PD diagnosis | 59 | 45 | 57 | 45 |
Initial DA medication |
Pramipexolea
Ropinirolea |
Pramipexole 3 mg/day | Ropinirole 8 mg/day | Pramipexolea |
Duration on DA | <1 year | 10 months | 5 years | 2 months |
Type of ICD | Hypersexual | Hypersexual | Hypersexual |
Compulsive buyingb
Compulsive cleaning (Compulsive drinking) |
Age of ICD onset | 66 | 46 | 62 | 45b; 49 |
Treatment trials | ||||
DA reduction/cessation attempted | — | Yes | Yes | Yes |
l‐dopa reduction attempted | Yes | Yes | — | Yes |
SSRI | Sertraline 100 mg/day | — | — | — |
SNRI | — | Venlafaxine XR 225 mg/day | — | Venlafaxine 150 mg/day |
Antipsychotic | Quetiapine 50 mg/day | Quetiapine 25 mg/day | — | Quetiapine 12.5 mg/day |
Other | — | Amantadine 300 mg/day | Amantadine 200 mg/day | Amantadine 200 mg/day |
Clozapine maximum dose | 37.5 mg | 37.5 mg | 12.5 mg | 25 mg |
Follow‐up duration of sustained resolution | 6 months | 1 year | 1 month | 15 months |
Side effect | — | — | Sedation | Weight gain |
Dosing unknown.
Initial ICD, responded to dopamine agonist cessation.
SSRI, selective serotonin reuptake inhibitor; SNRI, serotonin‐noradrenaline (norepinephrine) reuptake inhibitor.